Protagenic Therapeutics announces 1-for-4 reverse stock split to comply with Nasdaq minimum bid price rule

Protagenic Therapeutics, Inc.new

Reverse split effective 5:01 p.m. ET March 22, 2023; split-adjusted trading Nasdaq opens March 23, 2023.
Goal: meet Nasdaq Rule 5550(a)(2) $1.00 minimum closing price for continued listing.
Outstanding shares reduced from ~17,285,261 to ~4,321,315; no fractional shares—rounded up to next whole.
Proportionate adjustments to exercise prices and shares underlying outstanding options, warrants, and equity awards.
Authorized shares and par value unchanged; new CUSIP 74365N202; ticker remains PTIX.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Protagenic Therapeutics, Inc.new: Approved and filed a Certificate of Amendment to effect a 1-for-4 reverse stock split of common stock to comply with Nasdaq Rule 5550(a)(2) (effective 2023-03-22).

Change: charter amendment
Effective: 2023-03-22

Exact text from the filing

On March 21, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its third amended and restated certificate of incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001493152-23-008494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.